TOXIC CELLULAR DNA DAMAGE AND DISEASES

Award Information
Agency:
Department of Defense
Branch
Army
Amount:
$49,910.00
Award Year:
1986
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Agency Tracking Number:
3814
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Cytec Inc
Po Box 57462, Webster, TX, 77598
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
DR TOD S JOHNSON
(713) 484-4610
Business Contact:
() -
Research Institution:
n/a
Abstract
THE OBJECTIVE OF THIS PHASE I SBIR PROJECT IS TO STUDY TECHNICAL/ METHODOLOGICAL ASPECTS, PERFORMANCE CRITERIA FOR ANEW CLINICAL SPECIMEN TOXICITY TEST. STATE-OF-THE-ART FLOW CYTOMETRIC/MONOCLONAL ANTIBODY TECHNOLOGY WOULD BE USED TO DETECT DNA DAMAGE, CYTOKINETIC ABNORMALITIES, AND ANEUPLOIDY. GENOTOXICITY AND CYTOKINETIC ABNORMALITIES WOULD BE ASSESSED IN VITRO BY LABELING WITH A HALOGENERATED PHRIMIDINE (IDURD) AND THEN USING MULTIPARAMETER FLOW CYTOMETRIC ANALYSIS OF DNA CONTENT AND THE AMOUNT OF IDURD INCORPORATED (DNA REPLICATION PATTERN) VIA A FLUORESCENT TAGGED MONOCLONAL ANTIBODY HIGHLY SPECIFIC FOR IDURD. WE PROPOSE TO DEVELOP: 1) AN IMMUNOTOXICITY TEST BASED ON SHORT-TERM CULTURE, BLASTOGENEIC RESPONSE TO PHA MITOGEN STIMULATED, PERIPHERAL BLOOD LYMPHOCYTES (ULTIMATELY T-& BCELL SUBSETS); AND 2) A HEPATOTOXICITY TEST USING IN VITRO IDURD LABELING OF FINE NEEDLE ASPIRATION BIOPSIES. PHASE I STUDIES WOULD UTILIZE DOMESTIC CANINES, WHEREAS BOTH CANINE AND HUMAN CLINICAL MATERIAL WOULD BE STUDIED IN PHASE II. THE HIGH TECHNOLOGY TEST(S) TO BE DEVELOPED WOULD BE VERSATILE; HAVE BROAD COMMERCIAL AND MILITARY APPLICATIONS; AND REPRESENT A MAJOR STEP FORWARD ANALYTICALLY FOR TOXICITY TEST DETECTION OF DNA DAMAGE, CELLULAR ABNORMALITIES, AND DISEASES ACQUIRED NATURALLY OR BY EXPOSURE TO BIOLOGICAL WEAPONS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government